TrialThe Lancet. Oncology2019

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.

Haruhiro Saito et al.PubMed ↗Publisher ↗

No numbers read from the abstract.